Recent COVID-19 treatment guidelines highlight antiviral choices for high-risk patients Updated clinical guidance from the Infectious Diseases Society of America (IDSA) provides evidence-based recommendations for antiviral treatment in adults with mild to moderate COVID-19 who are at increased risk for severe disease. The guidelines emphasize early intervention with authorized antivirals to reduce the risk of hospitalization and death, particularly during periods of high community transmission. For patients with mild to moderate COVID-19 who have risk factors for progression to severe illness, the IDSA recommends nirmatrelvir-ritonavir (Paxlovid) or remdesivir (Veklury) as preferred treatment options. These antivirals are most effective when initiated within five to seven days of symptom onset. Clinical trials have demonstrated that nirmatrelvir-ritonavir significantly reduces the incidence of hospitalization or death in high-risk, non-hospitalized adults with COVID-19. In situations where nirmatrelvir-ritonavir or remdesivir are not suitable or available, the IDSA suggests molnupiravir (Lagevrio) as an alternative antiviral option for certain high-risk patients. This recommendation is conditional and based on low certainty of evidence, reflecting ongoing evaluation of molnupiravir’s effectiveness compared to other available treatments. The guidelines too address the employ of immunomodulatory therapies in hospitalized patients. For adults with severe or critical COVID-19 who require additional immunomodulation despite standard corticosteroid therapy, the IDSA provides evidence-based recommendations on agents such as baricitinib and tocilizumab, abatacept, and infliximab. These recommendations are tailored to specific patient populations and clinical scenarios, based on data from recent clinical trials and cohort studies. Monitoring remains a key component of outpatient management. Clinicians are advised to use pulse oximetry to assess oxygenation in patients with dyspnea, recognizing limitations in accuracy among individuals with darker skin pigmentation and with certain smartphone-based devices. Close monitoring is essential due to the risk of rapid progression to acute respiratory distress syndrome (ARDS) in some patients. The guidance underscores that most individuals with asymptomatic, mild, or moderate COVID-19 can be managed in an outpatient setting. Supportive care, including antipyretics, analgesics, and antitussives, is appropriate for those without risk factors for severe illness. Patient education on infection prevention and recognition of warning signs requiring medical attention is also emphasized. These recommendations are intended to inform clinical decision-making and are subject to update as new evidence emerges. Healthcare providers should consult the full IDSA guidelines and consider individual patient factors, including comorbidities, medication interactions, and local viral variants, when determining the optimal treatment approach. Access to timely testing and early treatment initiation remain critical to improving outcomes in high-risk populations.
24